These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 10529641)

  • 1. Enalapril on oxidative stress in5/6 nephrectomized rats.
    Sugimoto K; Tsuruoka S; Matsushita K; Fujimura A
    Nephron; 1999; 83(3):282-3. PubMed ID: 10529641
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats.
    Noda M; Fukuda R; Matsuo T; Ohta M; Nagano H; Imura Y; Nishikawa K; Shibouta Y
    Kidney Int Suppl; 1997 Dec; 63():S136-9. PubMed ID: 9407442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curcumin ameliorates renal failure in 5/6 nephrectomized rats: role of inflammation.
    Ghosh SS; Massey HD; Krieg R; Fazelbhoy ZA; Ghosh S; Sica DA; Fakhry I; Gehr TW
    Am J Physiol Renal Physiol; 2009 May; 296(5):F1146-57. PubMed ID: 19225048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of converting enzyme and thromboxane synthetase in a model of progressive renal disease; effects of enalapril and RS-86328 in the rat.
    Rosenkranz RP; Hayashi CM
    Proc West Pharmacol Soc; 1988; 31():81-5. PubMed ID: 2850566
    [No Abstract]   [Full Text] [Related]  

  • 5. Disparate effects of angiotensin converting enzyme inhibitor and calcium blocker treatment on the preservation of renal structure and function following subtotal nephrectomy or streptozotocin-induced diabetes in the rat.
    Jackson B; Cubela R; Debrevi L; Whitty M; Johnston CI
    J Cardiovasc Pharmacol; 1987; 10 Suppl 10():S167-9. PubMed ID: 2455124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular mechanisms of nephro-protective action of enalapril in experimental chronic renal failure].
    Ciechanowicz A
    Ann Acad Med Stetin; 1999; Suppl 52():1-93. PubMed ID: 10589103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin combined with ACE inhibitor prevents heart remodeling in 5/6 nephrectomized rats independently of blood pressure and kidney function.
    Gut N; Piecha G; Aldebssi F; Schaefer S; Bekeredjian R; Schirmacher P; Ritz E; Gross-Weissmann ML
    Am J Nephrol; 2013; 38(2):124-35. PubMed ID: 23920063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of ACE inhibitor with nicorandil provides further protection in chronic kidney disease.
    Shiraishi T; Tamura Y; Taniguchi K; Higaki M; Ueda S; Shima T; Nagura M; Nakagawa T; Johnson RJ; Uchida S
    Am J Physiol Renal Physiol; 2014 Dec; 307(12):F1313-22. PubMed ID: 25320353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure.
    Ziai F; Ots M; Provoost AP; Troy JL; Rennke HG; Brenner BM; Mackenzie HS
    Kidney Int Suppl; 1996 Dec; 57():S132-6. PubMed ID: 8941934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of exercise and enalapril enhances renoprotective and peripheral effects in rats with renal ablation.
    Kanazawa M; Kawamura T; Li L; Sasaki Y; Matsumoto K; Kataoka H; Ito O; Minami N; Sato T; Ootaka T; Kohzuki M
    Am J Hypertens; 2006 Jan; 19(1):80-6. PubMed ID: 16461196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D receptor agonist VS-105 improves cardiac function in the presence of enalapril in 5/6 nephrectomized rats.
    Wu-Wong JR; Chen YW; Wessale JL
    Am J Physiol Renal Physiol; 2015 Feb; 308(4):F309-19. PubMed ID: 25503724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors.
    Kohzuki M; Kanazawa M; Liu PF; Kamimoto M; Yoshida K; Saito T; Yasujima M; Sato T; Abe K
    J Hypertens; 1995 Dec; 13(12 Pt 2):1785-90. PubMed ID: 8903652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure.
    Noda M; Matsuo T; Fukuda R; Ohta M; Nagano H; Shibouta Y; Naka T; Nishikawa K; Imura Y
    Kidney Int; 1999 Sep; 56(3):898-909. PubMed ID: 10469358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats.
    Husain K; Ferder L; Mizobuchi M; Finch J; Slatopolsky E
    Am J Nephrol; 2009; 29(5):465-72. PubMed ID: 19033720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic actions of enalapril and tempol during chronic angiotensin II-induced hypertension.
    Elmarakby AA; Williams JM; Imig JD; Pollock JS; Pollock DM
    Vascul Pharmacol; 2007 Feb; 46(2):144-51. PubMed ID: 17112788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction.
    Perico N; Zoja C; Corna D; Rottoli D; Gaspari F; Haskell L; Remuzzi G
    Kidney Int; 2009 Nov; 76(9):960-7. PubMed ID: 19625993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renoprotective properties of pirfenidone in subtotally nephrectomized rats.
    Takakuta K; Fujimori A; Chikanishi T; Tanokura A; Iwatsuki Y; Yamamoto M; Nakajima H; Okada M; Itoh H
    Eur J Pharmacol; 2010 Mar; 629(1-3):118-24. PubMed ID: 20006961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renoprotective effects of combination of angiotensin converting enzyme inhibitor with mycophenolate mofetil in diabetic rats.
    Wu YG; Lin H; Qian H; Zhao M; Qi XM; Wu GZ; Lin ST
    Inflamm Res; 2006 May; 55(5):192-9. PubMed ID: 16830106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enalapril in subantihypertensive dosage attenuates kidney proliferation and functional recovery in normotensive ablation nephropathy of the rat.
    Krivosíková Z; Sebeková K; Spustová V; Lajdová I; Dzúrik R
    Physiol Res; 1999; 48(6):429-35. PubMed ID: 10783907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with angiotensin-converting enzyme inhibitor and oral adsorbent of uremic toxins can delay the appearance of glomerular sclerosis and interstitial fibrosis in established renal failure.
    Okada K; Okawa E; Shibahara H; Maruyama T; Maruyama N; Matsumoto K; Takahashi S
    Kidney Blood Press Res; 2004; 27(4):218-25. PubMed ID: 15273424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.